Type 2 diabetes mellitus is a disease caused by disturbances in the metabolism of carbohydrates, proteins, and fats, characterized by hyperglycemia. This disease is one of the risk factors for chronic kidney disease, which can affect life expectancy. This study aims to determine the pattern of antidiabetic drug use and the rationality of drug use, as well as its relationship with the patient's discharge condition. This retrospective study collected medical record data of type 2 diabetes mellitus patients with chronic kidney disease in 2018. The study found that 61 patients met the inclusion criteria. Based on sociodemographic characteristics, the majority of patients were female (68.9%), aged 46-55 years (36.1%), had completed high school education (47.5%), and were housewives (57.4%). The pattern of antidiabetic drug use in type 2 diabetes mellitus patients with chronic kidney disease was as follows: 13.11% of patients used novorapid, 11.47% used lantus, 11.47% used gliclazide, 1.63% used glimepiride, 37.7% used a combination of novorapid with levemir, 3.27% used a combination of novorapid with lantus, 3.27% used a combination of novorapid with gliclazide, 6.55% used a combination of lantus with apidra, 1.63% used a combination of levemir with gliclazide, and 9.83% used intravenous critical insulin drip. The rationality of drug use was 100% appropriate indication, 95.08% appropriate drug selection, 100% appropriate patient, 100% appropriate dose, 100% appropriate frequency, and 100% appropriate administration route. The chi-square test and Kruskal-Wallis test showed a p-value >0.05, indicating no significant relationship between sociodemographic characteristics and patient discharge condition, as well as no significant relationship between the rationality of antidiabetic drug use and patient discharge condition.

Keywords : Chronic Kidney Disease, Antidiabetic Drug, Rational, CKD, Type 2 Diabetes Mellitus